Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - ENANTA PHARMACEUTICALS INC | enta-ex311_10.htm |
| EX-10.18 - EX-10.18 - ENANTA PHARMACEUTICALS INC | enta-ex1018_1136.htm |
| EX-4.3 - EX-4.3 - ENANTA PHARMACEUTICALS INC | enta-ex43_1302.htm |
| 10-K - 10-K - ENANTA PHARMACEUTICALS INC | enta-10k_20170930.htm |
| EX-31.2 - EX-31.2 - ENANTA PHARMACEUTICALS INC | enta-ex312_8.htm |
| EX-23.1 - EX-23.1 - ENANTA PHARMACEUTICALS INC | enta-ex231_11.htm |
| EX-21.1 - EX-21.1 - ENANTA PHARMACEUTICALS INC | enta-ex211_12.htm |
| EX-10.19 - EX-10.19 - ENANTA PHARMACEUTICALS INC | enta-ex1019_1137.htm |
Exhibit 32.1
Certification of Periodic Financial Report
Pursuant to 18 U.S.C. Section 1350
as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Each of the undersigned officers of Enanta Pharmaceuticals, Inc. (the “Company”) certifies, to his knowledge and solely for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Annual Report on Form 10-K of the Company for the year ended September 30, 2017 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of Enanta.
Dated: December 11, 2017
|
/s/ Jay R. Luly, Ph.D. |
|
Jay R. Luly, Ph.D. |
|
Chief Executive Officer |
Dated: December 11, 2017
|
/s/ Paul J. Mellett |
|
Paul J. Mellett |
|
Chief Financial Officer |